Last reviewed · How we verify
Manipulation
Manipulation is a Biologic drug developed by Universidade do Porto. It is currently in Phase 2 development.
Manipulation is a term that can refer to various acts intended to influence or control someone in a subtle way, or the use of crowd psychology to direct the behavior of a crowd. In a medical context, Manipulation has been studied as a treatment for conditions such as Parkinson Disease, Low Back Pain, and Stroke, involving interventions such as Osteopathic Visceral Manipulation and pain expectation conditioning.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Manipulation |
|---|---|
| Sponsor | Universidade do Porto |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Manipulating Exercise Intensity and Affective Responses for Cardiac Rehabilitation Program Acute Coronary Syndrome Patients (NA)
- OMT for Adhesive Capsulitis (PHASE4)
- Procedural Framing and Epidural Steroid Injection Outcomes (NA)
- Milieu Teaching-AV: Adaptation of Milieu Teaching That Encourages Looking to the Mouth (NA)
- Manual Therapy in Improving Quality of Life in Women With Dyspareunia (NA)
- Development of a Neuronal Microscope (NA)
- Post-concussion Syndrome and Chiropractic (NA)
- Differences in Rest, Emotion, and Arousal Modulation in Youth (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Manipulation CI brief — competitive landscape report
- Manipulation updates RSS · CI watch RSS
- Universidade do Porto portfolio CI
Frequently asked questions about Manipulation
What is Manipulation?
Who makes Manipulation?
What development phase is Manipulation in?
Related
- Manufacturer: Universidade do Porto — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing